🔥🐔 BizChicken 🐔🔥

Companies Similar to Ginkgo Bioworks Holdings, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

DNAbilize

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.

Tags: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, DNAbilize, Drug Development, Lymphoma, Myelodysplastic Syndrome, Oncology, Pancreatic Cancer, Prexigebersen, RNAi

Symbol: BPTH

Recent Price: $1.17

Industry: Biotechnology

CEO: Mr. Peter H. Nielsen MBA

Sector: Healthcare

Employees: 10

Address: 4710 Bellaire Boulevard, Bellaire, TX 77401

Phone: 832 742 1357

Leadership

  • Peter Nielsen, Chief Executive Officer, Chief Financial Officer
  • Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
  • Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
  • Michael Hickey, MBA, Vice President of Clinical Operations
  • Michael Roberts, Director of Manufacturing Planning & Engineering
  • Chairman of the Board,
  • President,
  • Heath Cleaver, Director
  • Paul Aubert, Director
  • Douglas P. Morris, Director
  • Aline Sherwood, Director

Last updated: 2024-12-31

Passage Bio, Inc.

Passage Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06

Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.

Tags: AAVhu68, central nervous system, genetic medicines, proprietary technology, therapies

Symbol: PASG

Recent Price: $0.67

Industry: Biotechnology

CEO: Dr. William Chou M.D.

Sector: Healthcare

Employees: 58

Address: One Commerce Square, Philadelphia, PA 19103

Phone: 267 866 0311

Leadership

  • William Chou, MD, President and Chief Executive Officer
  • Kathleen Borthwick, Chief Financial Officer
  • Sue Browne, PhD, Chief Scientific Officer
  • Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
  • Eden Fucci, SVP Technical Operations
  • Stuart Henderson, Chief Business Officer
  • Karl Whitney, PhD, SVP Global Regulatory Affairs
  • James M. Wilson, MD, PhD, Scientific Advisor
  • Maxine Gowen, PhD, Chairwoman
  • Athena Countouriotis, MD,
  • Derrell D. Porter, MD,
  • Dolan Sondhi, PhD,
  • Sandip Kapadia,
  • Tom Kassberg,
  • Saqib Islam,
  • Samiah Al-Zaidy, MD, Vice President, Clinical Development
  • Andrea Campanile, Vice President, Clinical Operations

Last updated: 2024-12-31

GeneDx Holdings Corp.

GeneDx Holdings Corp. logo
Market Cap: High
Employees: Medium

Centrellis health intelligence platform

Gene Dx Holdings Corp. is a patient-centered health intelligence company focused on transforming healthcare by leveraging AI and machine learning on clinical and genomic data to improve individual health outcomes.

Tags: AI, genomics, health intelligence, healthcare, machine learning

Symbol: WGS

Recent Price: $76.58

Industry: Medical - Healthcare Information Services

CEO: Ms. Katherine A. Stueland

Sector: Healthcare

Employees: 1000

Address: North Tower, Stamford, CT 06902

Phone: 800 298 6470

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

IGALMI

Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.

Tags: agitation treatment, artificial intelligence, biopharmaceutical, clinical trials, immuno-oncology, neuroscience

Symbol: BTAI

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Vimal D. Mehta Ph.D.

Sector: Healthcare

Employees: 74

Address: 555 Long Wharf Drive, New Haven, CT 06511

Phone: 475 238 6837

Last updated: 2024-12-31

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

DAY101

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for genetically defined cancers. Their lead product candidate is DAY101, currently in Phase II clinical trials for pediatric patients with low-grade glioma.

Tags: DAY101, Pimasertib, biopharmaceuticals, cancer therapy, clinical-stage

Symbol: DAWN

Recent Price: $12.58

Industry: Biotechnology

CEO: Dr. Jeremy Bender M.B.A., Ph.D.

Sector: Healthcare

Employees: 174

Address: 395 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 484 0899

Leadership

  • Samuel Blackman, MD, PhD, Head of R&D
  • Elly Barry, MD, Chief Medical Officer
  • Jeremy Bender, PhD, MBA, Director
  • Davy Chiodin, PharmD, Chief Development Officer
  • Adam Dubow, General Counsel
  • Lauren Merendino, MBA, Chief Commercial Officer
  • John Stubenrauch, Chief Technology Officer
  • Jaa Roberson, Chief People Officer
  • Charles N. York II, MBA, Chief Operating and Financial Officer
  • Garry Nicholson, MBA, Chair
  • Habib Dable, Director
  • Scott Garland, Director
  • Michael Gladstone, Director
  • William Grossman, MD, PhD, Director
  • Natalie Holles, Director
  • John A. Josey, PhD, MBA, Director
  • Saira Ramasastry, MS, MPhil, Director

Last updated: 2024-12-31

Gossamer Bio, Inc.

Gossamer Bio, Inc. logo
Market Cap: Low
Employees: Low

GB002, GB004, GB5121, GB7208

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.

Tags: biopharmaceutical, central nervous system lymphoma, immunology, inflammation, inflammatory bowel disease, multiple sclerosis, oncology, pulmonary arterial hypertension, therapeutics

Symbol: GOSS

Recent Price: $0.88

Industry: Biotechnology

CEO: Mr. Faheem Hasnain

Sector: Healthcare

Employees: 135

Address: 3013 Science Park Road, San Diego, CA 92121

Phone: 858 684 1300

Leadership

  • Faheem Hasnain, Chairman
  • Richard Aranda, M.D., Chief Medical Officer
  • Jeff Boerneke, General Counsel and Secretary
  • Matt Cravets, Senior Vice President, Biometrics
  • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
  • Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
  • Caryn Peterson, Executive Vice President, Regulatory Affairs
  • Bob Smith, Chief Commercial Officer
  • Christian Waage, Executive Vice President, Technical Operations & Administration
  • Deanna Weber, Senior Vice President, Human Resources
  • Russell J. Cox, Director
  • Thomas Daniel, Director
  • Skye Drynan, Director
  • Sandra Milligan, Director
  • Steven D. Nathan, Director
  • John Quisel, Director

Last updated: 2024-12-31

Harvard Bioscience, Inc.

Harvard Bioscience, Inc. logo
Market Cap: Low
Employees: Medium

cellular and molecular technology instruments

Harvard Bioscience, Inc. develops, manufactures, and sells technologies and services that support research, discovery, and pre-clinical testing for drug development globally, offering a wide range of instruments for tissue and organ-based lab research.

Tags: biotech, drug development, laboratory instruments, precision measuring, research

Symbol: HBIO

Recent Price: $2.02

Industry: Medical - Instruments & Supplies

CEO: Mr. James W. Green

Sector: Healthcare

Employees: 391

Address: 84 October Hill Road, Holliston, MA 01746

Phone: 508 893 8999

Leadership

  • James Green, Chairman, President & Chief Executive Officer
  • Jennifer Cote, Chief Financial Officer and Treasurer
  • John Fry, Chief Legal Counsel and Corporation Secretary
  • Diane Houston, Vice President, Global IT
  • Lori Packer, Vice President, Global People Operations
  • Nitya Shetty, Vice President, Global Research and Development
  • Ryan Wallace, Senior Vice President, Global Sales

Last updated: 2024-12-31

Leafly Holdings, Inc.

Leafly Holdings, Inc. logo
Market Cap: Lowest
Employees: Low

Leafly Platform

Leafly Holdings, Inc. provides consumers with cannabis information, connecting them with brands and licensed retailers. The platform offers marketplace listings, digital advertising, SaaS tools for retailers, and consumer information via its website and mobile applications.

Tags: SaaS, advertising, cannabis, information, marketplace, retailers

Symbol: LFLY

Recent Price: $1.53

Industry: Medical - Pharmaceuticals

CEO: Ms. Yoko Miyashita

Sector: Healthcare

Employees: 121

Address: 111 South Jackson Street, Seattle, WA 98104

Phone: 206 455 9504

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Omega Therapeutics, Inc.

Omega Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

OMEGA Epigenomic Programming platform

Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.

Tags: biopharmaceutical, chronic liver diseases, corneal regeneration, epigenetics, gene control, idiopathic pulmonary fibrosis

Symbol: OMGA

Recent Price: $0.80

Industry: Biotechnology

CEO: Mr. Mahesh Karande

Sector: Healthcare

Employees: 93

Address: 20 Acorn Park Drive, Cambridge, MA 02140

Phone: 617 949 4360

Leadership

  • Mahesh Karande, President & Chief Executive Officer
  • Kaan Certel, Ph.D., Chief Business Officer
  • Jennifer Nelson, Ph.D., Senior Vice President, Research
  • Tony Mullin, Chief People Officer
  • Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
  • Lisamarie Fahy, Senior Vice President, Clinical Development Operations
  • Joe Newman, Ph.D., Senior Vice President, Early Discovery
  • Jeff Atkinson, Ph.D., Vice President, Technical Operations
  • Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs

Last updated: 2024-12-31

Organovo Holdings, Inc.

Organovo Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

Novo Gen Bioprinters

Organovo Holdings, Inc. is a biotechnology company that develops 3D tissues to model human diseases, utilizing proprietary bioprinting technologies such as Novo Gen Bioprinters for fabricating living tissues.

Tags: 3D tissues, Ex Vive, Novo Gen Bioprinters, bioprinting, biotechnology, human disease

Symbol: ONVO

Recent Price: $0.36

Industry: Biotechnology

CEO: Mr. Keith E. Murphy

Sector: Healthcare

Employees: 20

Address: 11555 Sorrento Valley Road, Solana Beach, CA 92121

Phone: 858 224 1000

Leadership

  • Keith Murphy, Executive Chairman, CEO
  • Thomas P. Hess, Chief Financial Officer
  • Curtis Tyree, Ph.D., Senior Vice President, Strategy and Business Development
  • Adam K. Stern, CEO
  • Alison Milhous, Vice President, Accounting
  • David Gobel, CEO
  • Doug Cohen, President and Chief Executive Officer
  • Vaidehi Joshi, Director of Discovery Biology

Last updated: 2024-12-31

Sana Biotechnology, Inc.

Sana Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

N/A

Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines, developing cell engineering platforms for various therapeutic areas including oncology, diabetes, and genetic disorders.

Tags: biotechnology, cell engineering, genetic disorders, medicine, oncology

Symbol: SANA

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Steven D. Harr M.D.

Sector: Healthcare

Employees: 328

Address: 188 East Blaine Street, Seattle, WA 98102

Phone: 206 701 7914

Last updated: 2024-12-31

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. logo
Market Cap: Medium
Employees: Medium

platform for cell programming

Ginkgo Bioworks Holdings, Inc. develops a platform used to program cells for biological production of products such as therapeutics, food ingredients, and chemicals. It serves markets in specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Tags: agriculture, biotechnology, cell programming, food ingredients, novel therapeutics, pharmaceuticals, specialty chemicals

Symbol: DNA

Recent Price: $9.44

Industry: Biotechnology

CEO: Dr. Jason Kelly

Sector: Healthcare

Employees: 1218

Address: 27 Drydock Avenue, Boston, MA 02210

Phone: 877 422 5362

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

BioLife Solutions, Inc.

BioLife Solutions, Inc. logo
Market Cap: Medium
Employees: Medium

bioproduction tools and services

Bio Life Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services essential for the cell and gene therapy industry globally. The company's offerings include biopreservation media products, automated thawing products, cloud-connected shipping containers, and storage solutions for biologics and pharmaceuticals.

Tags: biological storage, biologics, biopreservation, cell therapy, cryogenic equipment, gene therapy, pharmaceuticals, temperature-sensitive storage

Symbol: BLFS

Recent Price: $26.27

Industry: Medical - Instruments & Supplies

CEO: Mr. Roderick de Greef

Sector: Healthcare

Employees: 409

Address: 3303 Monte Villa Parkway, Bothell, WA 98021

Phone: 425 402 1400

Leadership

  • Rod de Greef, Chairman & Chief Executive Officer
  • Aby J. Mathew, Ph.D., Executive Vice President and Chief Scientific Officer
  • Karen Foster, Chief Quality and Operations Officer
  • Troy Wichterman, Chief Financial Officer
  • Todd Berard, Chief Marketing Officer
  • Garrie Richardson, Chief Revenue Officer
  • Sarah Aebersold, Chief Human Resources Officer
  • Mike Pallotta, Global VP, Hardware and Electrical Engineering
  • Brett Stucker, VP of Cybersecurity and Information Security Officer
  • Amy DuRoss,
  • Rachel Ellingson,
  • Joydeep Goswami, MBA, Ph.D.,
  • Tim Moore,
  • Joseph Schick, Chairman – Audit Committee
  • Andrew Hinson,
  • Anthony Davies, Ph.D.,
  • Colleen Delaney, M.D., M.Sc.,
  • Dayong Gao, Ph.D.,
  • Erik Woods, Ph.D., HCLD(ABB),
  • Jon Rowley, Ph.D.,
  • John McMannis, Ph.D.,
  • Jerry E. Cooley, M.D.,
  • Jason Acker, MBA, Ph.D.,
  • Lizabeth Cardwell, MT (ASCP), MBA, RAC,
  • Scott R. Burger, M.D.,
  • Shelly Heimfeld, Ph.D.,

Last updated: 2024-12-31

Galecto, Inc.

Galecto, Inc. logo
Market Cap: Lowest
Employees: Lowest

GB2064

Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.

Tags: biotechnology, cancer, clinical trials, fibrosis, inflammation, pharmaceutical

Symbol: GLTO

Recent Price: $4.60

Industry: Biotechnology

CEO: Dr. Hans T. Schambye M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 75 State Street, Boston, MA 02109

Phone: 457 070 5210

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31